Novartis India Limited has issued a regulatory notice regarding its postal ballot and e-voting process, fulfilling mandatory disclosure requirements under securities regulations. The pharmaceutical company published newspaper advertisements on April 13, 2026, to inform shareholders about the upcoming postal ballot procedure.

Regulatory Compliance Notice

The company filed a formal intimation with BSE Limited regarding the publication of newspaper advertisements in Financial Express and Navshakti. The notice was submitted pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Corporate Communication Details

Company Secretary and Compliance Officer Chandni Maru signed the regulatory communication on behalf of Novartis India Limited. The notice was digitally signed and submitted to BSE Limited's corporate communications department.

Postal Ballot Process Framework

The postal ballot process will be conducted in accordance with multiple regulatory frameworks, including Sections 110 and 108 of the Companies Act, 2013, and Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014. The company will also follow SEBI Listing Regulations and Secretarial Standards on General Meetings issued by The Institute of Company Secretaries of India.

Shareholder Communication Protocol

The notice will be distributed electronically to all members whose email addresses are registered with the company or Depository Participants. The postal ballot notice will also be made available on the company's website at www.novartis.in and on BSE Limited's website at www.bseindia.com .

Registration and Compliance Requirements

Shareholders holding shares in physical mode can register their email addresses with the company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited. The registration process requires completion of Form ISR-1 along with supporting documents including PAN and Aadhaar card copies. Email registration is contingent upon completion of KYC requirements as per SEBI regulations.

Novartis AG, the Swiss pharmaceutical major and promoter of Novartis India Limited, has filed a mandatory regulatory disclosure with BSE Limited confirming that no lien has been created on its equity holdings and reiterating details of its previously announced divestment agreement.

Lien Declaration on Equity Holdings

In compliance with Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Novartis AG declared that it has not created any lien on its 1.74 crore equity shares in Novartis India Limited, either directly or indirectly, as of March 31, 2026.

Sale Agreement Confirmation

The disclosure reaffirmed the sale and purchase agreement (SPA) entered into on February 19, 2026, for the complete divestment of Novartis AG's stake in its Indian subsidiary. The transaction involves three strategic acquirers who will collectively acquire the entire promoter holding.

Acquirer Details

The sale agreement encompasses three distinct entities:

• WaveRise Investments Limited (Acquirer 1)
• ChrysCapital Fund X (Acquirer 2)
• Two Infinity Partners (Acquirer 3)

Regulatory Compliance

The filing demonstrates Novartis AG's adherence to Indian securities regulations governing substantial shareholding transactions. The disclosure was addressed to BSE Limited and copied to the Audit Committee of Novartis India Limited, ensuring comprehensive regulatory notification.

The document was signed by authorized signatories Lukas Förtsch and Stefan Thommen, representing Novartis AG's commitment to maintaining transparency throughout the divestment process. This regulatory filing provides stakeholders with updated information on the transaction's progress and confirms the integrity of the shareholding structure pending completion of the sale.